Press Releases

Date Title and Summary Additional Formats
Toggle Summary Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into Phase 2 clinical trials for
View HTML
Toggle Summary Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference; Sigma-1 Agonist, C-10068, Shown to Have Anti-Convulsant and Neuroprotective Effects
Sigma-1 Agonist, C-10068, Shown to Have Anti-Convulsant and Neuroprotective Effects
View HTML
Toggle Summary Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance; LuAnn Sabounjian Named Vice President, Clinical Operations
Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance LuAnn Sabounjian Named Vice President, Clinical Operations
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Needham Healthcare Conference on April 5, 2011
Concert Pharmaceuticals to Present at the Needham Healthcare Conference on April 5, 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the 10th Annual Needham Healthcare Conference on Tuesday,
View HTML
Toggle Summary Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study; First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
View HTML
Toggle Summary Concert Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference on March 8
Concert Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference on March 8 Lexington, MA –- Concert Pharmaceuticals, Inc. today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Cowen and Company 31st Annual Health Care
View HTML
Toggle Summary Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound; Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases a
Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries
View HTML
Toggle Summary James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals; Additional Management Team Announcement with Promotion of Robert Silverman
Additional Management Team Announcement with Promotion of Robert Silverman
View HTML
Toggle Summary New Patents Continue to Issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property Estate
New Patents Continue to Issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property Estate Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity
View HTML
Toggle Summary Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board
Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board Lexington, MA -- Concert Pharmaceuticals, Inc. announced today the appointment of Lijun Wu, Ph.D., as Vice President, Biology.  In this newly created position, Dr. Wu will have responsibility for Concert’s
View HTML